NCT02140996View on ClinicalTrials.gov

Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

June 30, 2017

Conditions
Epithelial Cancers of the Lung, Breast, Ovary, Prostate and Colon
Interventions
DRUG

Ad-sig-hMUC-1/ecdCD40L vector vaccine

Trial Locations (2)

169610

RECRUITING

National Cancer Centre Singapore, Singapore

Unknown

RECRUITING

National Cancer Centre, Singapore

Sponsors

Collaborators (1)

ClinDatrix, Inc.
All Listed Sponsors
collaborator

MicroVAX, LLC

UNKNOWN

collaborator

ClinDatrix, Inc.

INDUSTRY

lead

Singapore Clinical Research Institute

OTHER

NCT02140996 - Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers | Biotech Hunter | Biotech Hunter